Gevotroline

Gevotroline
Systematic (IUPAC) name
8-fluoro-2-(3-pyridin-3-ylpropyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
Clinical data
Legal status
  • Uncontrolled
Routes of
administration		 Oral
Identifiers
CAS Number 107266-06-8
ATC code None
PubChem CID 60547
ChemSpider 54579
UNII 7SZ6A2091Q YesY
Chemical data
Formula C19H20FN3
Molar mass 309.38 g/mol

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]

See also

References

  1. ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  2. 1 2 3 Bristol, James A. (1990). Annual Reports in Medicinal Chemistry (Volume 25). Boston: Academic Press. ISBN 0-12-040525-3.
  3. 1 2 Stone, T. W.; Stone, Trevor (1996). CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press. ISBN 0-8493-7632-7.
  4. ↑ Snyder SH, Largent BL (1989). "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences 1 (1): 7–15. PMID 2577720.
  5. ↑ Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C (January 1991). "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology 30 (1): 79–87. doi:10.1016/0028-3908(91)90046-E. PMID 1675451.
  6. ↑ Gudelsky GA, Nash JF (February 1992). "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology 31 (2): 157–62. doi:10.1016/0028-3908(92)90026-L. PMID 1348112.
This article is issued from Wikipedia - version of the Thursday, December 10, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.